Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

2022 environmental science au pty ltd - imidacloprid - suspension concentrate - imidacloprid guanidine active 200.0 g/l - insecticide - building | commercial/industrial premises | domestic pest control | existing building/structure - treatment | fence - timber | g - drywood termite | subterranean termite - coptotermes spp. | subterranean termite - schedorhinotermes | subterranean termite ex. m. darwiniensis | subterranean termite incl. m.darwiniensi | coptotermes spp. | cryptotermes brevis | cryptotermes domesticus | cryptotermes primus | mastotermes darwiniensis | schedorhinotermes spp.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adapalene 0.1%{relative};   - topical gel - 0.1 % - active: adapalene 0.1%{relative}   excipient: carbomer 940 disodium edetate dihydrate methyl hydroxybenzoate phenoxyethanol poloxamer propylene glycol purified water sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ethambutol hydrochloride 100mg - tablet - 100 mg - active: ethambutol hydrochloride 100mg excipient: gelatin magnesium stearate methylated spirits opaglos clear na-7150 purified talc quinoline yellow shellac sorbitol stearic acid sucrose - myambutol is indicated for the treatment of pulmonary tuberculosis, primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ethambutol hydrochloride 401.328mg equivalent to 400 mg ethambutol; ethambutol hydrochloride 400mg - tablet - 400 mg - active: ethambutol hydrochloride 401.328mg equivalent to 400 mg ethambutol excipient: gelatin light liquid paraffin magnesium stearate opadry sorbitol stearic acid sucrose active: ethambutol hydrochloride 400mg excipient: calcium hydrogen phosphate ethylcellulose gelatin hypromellose isopropyl alcohol macrogol 6000 magnesium stearate maize starch methylene chloride sorbitol titanium dioxide - myambutol is indicated for the treatment of pulmonary tuberculosis, primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases.

Israel - English - Ministry of Health

megapharm ltd - rifaximine - film coated tablets - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria.• non-complicated diverticular diseases.

Israel - English - Ministry of Health

dexcel ltd, israel - lercanidipine hydrochloride - tablets - lercanidipine hydrochloride 10.0 mg - lercanidipine - lercanidipine - mild to moderate essential hypertension.

Israel - English - Ministry of Health

medison pharma ltd - interferon beta 1a - solution for injection - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Israel - English - Ministry of Health

novartis israel ltd - everolimus - tablets - everolimus 5 mg - everolimus - everolimus - - for the treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.- treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.- for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor.- afinitor ® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of afinitor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes.- afinitor ® is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease

Israel - English - Ministry of Health

novartis israel ltd - everolimus - tablets - everolimus 10 mg - everolimus - everolimus - - for the treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.- treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.- for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor.- afinitor ® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of afinitor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes.- afinitor ® is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease

Israel - English - Ministry of Health

novartis israel ltd - everolimus - tablets - everolimus 2.5 mg - everolimus - everolimus - - for the treatment of patients with sega associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.- treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.- for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor.- afinitor ® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. the effectiveness of afinitor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. further follow-up of patients is required to determine long-term outcomes.- afinitor ® is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.- treatment of unresectable, locally advanced or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease